CD274 and gastric cancer: The use of CAR-NK in GC is being explored in an ongoing phase II trial (NCT04847466) that evaluates the efficacy of irradiated PD-L1 CAR-NK cells in combination with pembrolizumab and N-803 in patients with advanced GC or head and neck cancer.